Guffanti, F.; Mengoli, I.; Ricci, F.; Perotti, L.; Capellini, E.; Sala, L.; Canesi, S.; Wu, C.-C.; Fruscio, R.; Ridinger, M.;
et al. Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas. Int. J. Mol. Sci. 2025, 26, 5708.
https://doi.org/10.3390/ijms26125708
AMA Style
Guffanti F, Mengoli I, Ricci F, Perotti L, Capellini E, Sala L, Canesi S, Wu C-C, Fruscio R, Ridinger M,
et al. Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas. International Journal of Molecular Sciences. 2025; 26(12):5708.
https://doi.org/10.3390/ijms26125708
Chicago/Turabian Style
Guffanti, Federica, Ilaria Mengoli, Francesca Ricci, Ludovica Perotti, Elena Capellini, Laura Sala, Simone Canesi, Chu-Chiao Wu, Robert Fruscio, Maya Ridinger,
and et al. 2025. "Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas" International Journal of Molecular Sciences 26, no. 12: 5708.
https://doi.org/10.3390/ijms26125708
APA Style
Guffanti, F., Mengoli, I., Ricci, F., Perotti, L., Capellini, E., Sala, L., Canesi, S., Wu, C.-C., Fruscio, R., Ridinger, M., Damia, G., & Chiappa, M.
(2025). Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas. International Journal of Molecular Sciences, 26(12), 5708.
https://doi.org/10.3390/ijms26125708
